Mitigate (ACD&P)
Abstract
The Mitigate Advanced Component Development and Prototypes (ACD&P) Project provides the Joint Force the ability to conduct decontamination and medical actions that enable the quick restoration of combat power; maintain/recover essential functions that are free from the effects of Chemical Biological Radiological and Nuclear (CBRN) hazards; and facilitate the return to pre-incident operational capability as soon as possible. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. MT4 efforts in FY 2022 remain in Projects DE4 and TM4. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts. Efforts included in this Project are: (1) Automated Decon System (ADS) (2) Antiviral Oral Therapeutic (AVO TX) (3) Biological Warfare Defense Prototype (BIOPROTO) (4) Botulinum Toxin Therapeutic (BOT TX) (5) Consolidated Nerve Agent Treatment System (CNATS) (6) Discovery of Medical Countermeasures Against New and Emerging Threats (DOMANE) (7) Reactivating Nerve Agent Treatment System (RNATS) (8) Service Equipment Decontamination System (SEDS) (9) Tactical Contamination Mitigation System (TCMS) The Automated Decontamination System (ADS) is a new start program in FY24. ADS is a semi-autonomous supported capability that relies on precision detection capabilities, modernized decontaminants, and robotics to allow a chemical, biological, radiological and nuclear (CBRN) decontamination squad to provide platoon level thorough decontamination on critical mission equipment and infrastructure. In FY24 ADS will award a concept prototype contract, accept delivery of an initial concept prototype and conduct an Alternative Systems Review. The Antiviral Oral Therapeutics (AVO TX) is a new start program in FY24. AVO TX will provide the Joint Force the ability to recover from exposure to biological hazards and quickly return to the fight. Efforts include development of Food and Drug Administration (FDA) approved Medical Countermeasure (MCM) to protect the lives and maintain the battle readiness of the Warfighter. AVO TX fulfills an existing gap for a MCM to treat exposure to alpha virus. The Biological Warfare Defense Prototype (BIOPROTO) supports early-phase clinical development and supporting non-clinical safety, tolerability and toxicity data for candidate vaccines and therapeutic drugs prior to transition to System Development & Demonstration. This work provides safe and effective medical defense against validated biological threat agents and emerging infectious disease biothreats including bacteria, toxins, and viruses. This work also involves the evaluation of Food and Drug Administration (FDA) approved therapeutics for operational use, as well as generation of novel drug products and formulations, to enhance level of protection and/or operational utility for the Warfighter. This effort reduces programmatic risk of failure in the advanced development phase. The Botulinum Toxin Therapeutic (BOT TX) is a new start program in FY24. BOT TX will develop and deliver a Food and Drug Administration (FDA) approved treatment for the warfighter to treat respiratory depression caused by botulinum toxin exposure. Botulinum toxin exposure is lethal and there are no available therapeutics that can be administered for BOT treatment in the field environment. This intramuscular injectable treatment is already approved for human use by the FDA. The Consolidated Nerve Agent Treatment System (CNATS) is a new start program in FY24. CNATS will deliver an FDA-approved autoinjector that combines anticholinergics, atropine and scopolamine, and a new broad-spectrum oxime. The proposed oxime will have efficacy against emerging threats including Fourth Generation Agents (FGAs). Combining nerve agent treatments into fewer autoinjectors will reduce basic load for service members. The Discovery of Medical Countermeasures Against Novel Entities (DOMANE) supports prototype development of emerging technology platforms and technologies to identify medical countermeasures (MCMs), MCM targets, and disease pathogenesis and toxicity using the combination of Artificial Intelligence/Machine Learning, organs-on-a-chip, high-throughput screening as well as novel imaging platforms. Additionally, MT4 supports early-phase clinical development of prophylaxis treatments and therapeutic drugs through the use of adaptive clinical trials to provide safe and effective medical defense against validated biological threat agents and emerging infectious disease biothreats including bacteria, toxins, and viruses. This effort reduces programmatic risk of failure in the advanced development phase by developing validated prototypes and generating clinical and supporting non-clinical safety, tolerability and toxicity data for candidate prophylaxis treatments and therapeutic drugs prior to transition to System Development & Demonstration. The Reactivator Nerve Agent Treatment System (RNATS) is a new start program in FY24. RNATS will provide the Services an FDA-approved broad-spectrum oxime to address emerging chemical threats and fourth generation agents (FGAs). The program will field a vial formulation as an additional capability to mitigate gaps in current nerve agent therapeutics. The Service Equipment Decontamination System (SEDS) program consists of two efforts, Joint SEDS and Special Operations Forces (SOF) Critical Equipment Decontamination (CEDS), which will develop a capability for use by the Warfighter during the decontamination operations that will provide a quantifiable reduction in the number of personnel experiencing adverse health effects by reducing contamination on equipment, individual combat equipment, and sensitive platform interiors. This capability is needed to sustain both the Joint and SOF by reducing logistical burdens in order to increase tactical agility and sustain a resilient force posture, and align with the National Defense Strategy (NDS). SEDS and CEDS will provide contamination mitigation capabilities for critical equipment that have been exposed to chemical and biological contamination and achieve efficacy levels that allow unprotected post-decontamination exposures for long periods with less than negligible severity effects. In FY24, the Joint SEDS effort will continue through the Engineering and Manufacturing Development (EMD) phase with Developmental Testing (DT) and a Critical Design Review (CDR). FY23 is last year of BA4 funding, program is transitioning to EMD. The Tactical Containment Mitigation System (TCMS) is a Contamination Mitigation concept and intends to address gaps related to the decontamination of critical equipment and vehicles and it will reduce the time and logistics associated with decontamination. TCMS will limit the spread and mitigate the effects of Chemical, Biological, and Radiological (CBR) contamination to allow warfighters to continue their mission for an extended period of time in a high threat, CBR contaminated environment. The Program's intent is to mitigate the risk to personnel and limit the potential spread of CBR contamination by minimizing contact and transfer hazards. TCMS will greatly enhance or eliminate the need for subsequent decontamination to mitigate contamination on military equipment. Following application of TCMS, combined with weathering, Mission Oriented Protective Posture (MOPP) levels may be reduced without further decontamination, depending on the surface or material being decontaminated and the agent. In FY24 the program will continue prototype testing and complete technical reviews in support of the Milestone B/Engineering Manufacturing & Development (EMD) Phase. FY24 is last year of BA4 funding, program is transitioning to the Engineering Manufacturing & Development (EMD) Phase.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2024
- Source ID
- MT4_0603884BP_4_0400_PB_2024
Related Documents
- Root: Chemical and Biological Defense Program - Dem/Val
- Child Accomplishment: 1) ADS - Prototype Development
- Child Accomplishment: 2) AVO TX - Non Clinical Study
- Child Accomplishment: 3) BIOPROTO
- Child Accomplishment: 4) BOT TX
- Child Accomplishment: 5) BOT TX
- Child Accomplishment: 6) CNATS - Acquisition Activities
- Child Accomplishment: 7) CNATS - Pre Milestone B
- Child Accomplishment: 8) DOMANE
- Child Accomplishment: 9) RNATS
- Child Accomplishment: 10) SEDS
- Child Accomplishment: 11) TCMS
- Child Cost Item: 75c5dfaf74fe158b529fa1477542b3a4
- Child Cost Item: fd710da5e9e9296e79f0650e6c72c053
- Child Cost Item: af8c3efb762e22cdf0034245566946d6
- Child Cost Item: a735e5eff82108f656724f1568e0ceb0
- Child Cost Item: fb7a47a6839c63e98e334c80608dc088
- Child Cost Item: ae677d8db55224ec0e48d411b21df0ef
- Child Cost Item: 37556575bff9cf4e277d19f4c6961b5b
- Child Cost Item: 1936f11b2235f28322de0e40c3436e14
- Child Cost Item: 36ecbea51262eb426a51b5ce32def22a
- Child Cost Item: 736514277bca6632de23a6eb33a7717a
- Child Cost Item: f0bce1232e17d03130901ae16a50b473
- Child Cost Item: b09f5fa2dcd1267c037b87f7fa37ac4b
- Child Cost Item: 425fd2aad8690fbe4a17ee1e1d5b1e96
- Child Cost Item: fefcf625a842ac3f762ef213e13cc347
- Child Cost Item: e7b2273cc4c403abcfdf31024c8b849c
- Child Cost Item: d8278e2262fa68bad4cec3f86b018d47
- Child Cost Item: e208cb3b4091922760d19ae1798ccbcc
- Child Cost Item: 7a86b278f78438d654053b2cf99ad044
- Child Cost Item: de35d024d1fe8b3623e2d63b53e9c200
- Child Cost Item: edb60efc24a53a1c4d672bb1dbb48c5e
- Child Cost Item: 9bcffa4a788e0b31380f5c2cd864aa3c
- Child Cost Item: 727d1baaf447cad6dae752f5cd622e97
- Child Cost Item: 116fad5e4d1333a68d3798b8c7eb5462
- Child Cost Item: 68195bad3585df31b11fad53a5c51d93